EMP-1001 · Your Group Confidential · De-identified November 3, 2025
October 2025 — Month 1 of 24
Monthly Employer Report · Therapeutic Class Breakdown · AWP Avoided
01Program ROI
Amount Spent · Cumulative
$5K
Program Spend$5K
AWP Fills Funded$0
Amount Saved
$0
AWP avoided · cumulative
Net Gain
−$5K
Investment phase · expected in M1
Program cost vs. AWP avoided · Month 1
AWP before taper
AWP avoided
Program cost
M1 ←
−$5K net
Program just launched — no fills have been tapered yet. Full program cost ($5K) with $0 in avoided drug spend. Savings begin as trust is established in M2–M3.
† Program fee ($500/pt/month) only. Diagnostic costs billed separately at $225/patient/quarter — approximately $750/month for this 10-patient group.
Early adopters cross into tapering M4–6 · most members M9 · conservative M12+
02Population
Population funnel · October 2025
From total covered population to active program participants — where each patient is in the Thymos journey.
1,000
Covered Lives
TOTAL PLAN ENROLLMENT
~80
With Autoimmune Conditions
IDENTIFIED VIA CLAIMS ANALYSIS · ~8% OF COVERED LIVES
10
In Active Program
ENROLLED WITH THYMOS · MONTH 1 OF 24
8
Onboarding
2
Building Trust
0
Tapering Therapy
0
New Normal
03Therapy Detail · October 2025
Therapeutic Class
Patients
Exp. Fills
Filled
Missed
Deferred
Abandoned
Gap Rate
AWP Avoided
TNF-α Inhibitors
4
6
6
—
—
—
0%
—
IL-17 Inhibitors
2
2
2
—
—
—
0%
—
IL-23 Inhibitors
2
2
2
—
—
—
0%
—
IL-6 Inhibitors
1
2
2
—
—
—
0%
—
Other Biologics & Specialty
1
1
1
—
—
—
0%
—
Total · This Month
10
13
13
—
—
—
0%
—
Net monthly impact = Σ (skipped fills × AWP per fill) − (active patients × $500). · This month: $0 AWP avoided − $5,000 program cost = −$5,000 (baseline month — no tapering yet).
AWP figures are published list price (NDC-level) at time of expected fill. · Program enrollment complete — tapering protocols begin M2.
Thymos Health
EMP-1001 · Your Group
Confidential · De-identified
July 1, 2026
June 2026 — Month 9 of 24
Monthly Employer Report · Therapeutic Class Breakdown · AWP Avoided
01Program ROI
Amount Spent · Cumulative
$81K
Program Spend$45K
AWP Fills Funded$36K
Amount Saved
$196K
AWP avoided · cumulative
Net Gain
+$115K
↑ $61K vs. last month
Monthly drug spend · before vs. with Thymos
Gray = what you'd spend on drugs without intervention. Teal = actual drug fills + $500/pt/mo fee. Teal area = savings.
Without Thymos
With Thymos
Savings
$85K → $24K/mo
Without Thymos: ~$85K/month in drug spend. With Thymos at M9: $19K in remaining fills + $5K program fee = $24K/month total. Saving $61K/month now — and cumulative savings ($196K AWP avoided) already exceed total program investment ($81K) by +$115K.
† Program fee ($500/pt/month) only. Diagnostic costs billed separately at $225/patient/quarter — approximately $750/month for this 10-patient group.
From total covered population to active program participants — where each patient is in the Thymos journey.
1,000
Covered Lives
TOTAL PLAN ENROLLMENT
~80
With Autoimmune Conditions
IDENTIFIED VIA CLAIMS ANALYSIS · ~8% OF COVERED LIVES
10
In Active Program
ENROLLED WITH THYMOS · MONTH 9 OF 24
1
Onboarding
2
Building Trust
5
Tapering Therapy
2
New Normal
03Therapy Detail · June 2026
Therapeutic Class
Patients
Exp. Fills
Filled
Missed
Deferred
Abandoned
Gap Rate
AWP Avoided
TNF-α Inhibitors
4
6
3
—
2
1
50%
$6,724
IL-17 Inhibitors
2
2
0
—
2
—
100%
$18,949
IL-23 Inhibitors
2
2
1
—
1
—
50%
$28,606
IL-6 Inhibitors
1
2
0
—
1
1
100%
$5,000
Other Biologics & Specialty
1
1
0
—
—
1
100%
$7,200
Total · This Month
10
13
4
—
6
3
69%
$66,479
Net monthly impact = Σ (deferred + abandoned fills × AWP per fill) − (active patients × $500). · This month: $66,479 AWP avoided − $5,000 program cost = +$61,479 net savings.
AWP figures are published list price (NDC-level) at time of expected fill. · Members may appear in multiple classes if on more than one biologic. · Fills Funded = 4 dispenses totaling $36K cumulative.
Thymos Health
EMP-1001 · Your Group Confidential · De-identified October 1, 2027
September 2027 — Month 24 of 24
Monthly Employer Report · Therapeutic Class Breakdown · AWP Avoided
01Program ROI
Amount Spent · Cumulative
$165K
Program Spend$120K
AWP Fills Funded$45K
Amount Saved
$780K
AWP avoided · cumulative
Net Gain
+$615K
↑ $75K vs. last month
Monthly drug spend · before vs. with Thymos
Gray = what you'd spend on drugs without intervention. Teal = actual drug fills + $500/pt/mo fee. Teal area = savings.
Without Thymos
With Thymos
Savings
M1
M2
M3
M4
M5
M6
M7
M8
M9
M10
M11
M12
M13
M14
M15
M16
M17
M18
M19
M20
M21
M22
M23
M24 ←
$85K → $10K/mo
Without Thymos: ~$85K/month in drug spend, every month, indefinitely. With Thymos at M24: $5K in remaining fills + $5K program fee = $10K total monthly cost. That's $75K saved per month — and cumulative savings ($780K AWP avoided) exceed total program investment ($165K) by +$615K.
† Program fee ($500/pt/month) only. Diagnostic costs billed separately at $225/patient/quarter — approximately $750/month for this 10-patient group.
From total covered population to active program participants — where each patient is in the Thymos journey.
1,000
Covered Lives
TOTAL PLAN ENROLLMENT
~80
With Autoimmune Conditions
IDENTIFIED VIA CLAIMS ANALYSIS · ~8% OF COVERED LIVES
10
In Active Program
ENROLLED WITH THYMOS · MONTH 24 OF 24
0
Onboarding
0
Building Trust
3
Tapering Therapy
7
New Normal
03Therapy Detail · September 2027
Therapeutic Class
Patients
Exp. Fills
Filled
Missed
Deferred
Abandoned
Gap Rate
AWP Avoided
TNF-α Inhibitors
4
3
1
—
—
2
67%
$4,647
IL-17 Inhibitors
2
2
0
—
—
2
100%
$18,949
IL-23 Inhibitors
2
2
0
—
—
2
100%
$46,960
IL-6 Inhibitors
1
1
0
—
—
1
100%
$2,500
Other Biologics & Specialty
1
1
0
—
—
1
100%
$7,200
Total · This Month
10
9
1
—
—
8
89%
$80,256
Net monthly impact = Σ (abandoned fills × AWP per fill) − (active patients × $500). · This month: $80,256 AWP avoided − $5,000 program cost = +$75,256 net savings.
AWP figures are published list price (NDC-level) at time of expected fill. · 7 of 10 members now in New Normal — minimal fills required. · Program concludes this month.
Thymos Health
EMP-1001 · Your Group
Internal Reference Only
July 1, 2026
Internal · Not for distribution
This page is for employer trust-building only — it will not be included in the delivered report. All data is de-identified per HIPAA Safe Harbor. No names, diagnoses, or direct identifiers appear below.
Patient Claim Detail — Month 9
De-identified · AWP list price estimates · M7–M9 claim window shown · Program stage per member